New Persistent Opiod Use Among Patients with Cancer After Curative-Intent Surgery - Michigan Oncology Quality Consortium (MOQC)

734.232.0043 moqc@moqc.org

LinkedIn

LinkedIn

HOME
CONTACT US
MEMBER RESOURCES
LOGIN

About
Abstraction
- ABSTRACTION RESOURCES
Patients/Caregivers
- PATIENT AND CAREGIVER ONCOLOGY QUALITY COUNCIL
  - POQC: Patient and Caregiver Oncology Quality Council
- PATIENT AND CAREGIVER RESOURCES
Initiatives
News & Events
- NEWS RESOURCES
  - Newsletters
  - Publications & Articles
- EVENTS
  - Events
  - Past Meeting Library
Resources

Select Page

Journal of Clinical Oncology, December 20, 2017

bcbsmRev340

Support for the Michigan Oncology Quality Consortium is provided by Blue Cross and Blue Shield of Michigan (BCBSM) as part of the BCBSM Value Partnerships program. BCBSM’s Value Partnerships program provides clinical and executive support for all CQI programs. Although Blue Cross Blue Shield of Michigan and MOQC work collaboratively, the opinions, beliefs and viewpoints expressed by the author do not necessarily reflect the opinions, beliefs and viewpoints of BCBSM or any of its employees.

MOQClogoRevVision

© Copyright – Michigan Oncology Quality Consortium (MOQC) • Arbor Lakes • 4251 Plymouth Road • Ann Arbor, MI 48105 • 734.232.0043

Name:

Type:

View

TRANSLATE »